Complix NV
Building therapeutic proteins that act like small molecules
This article was originally published in Start Up
Executive Summary
Complix NV aims to construct therapeutic proteins that can bind to molecular targets no antibody has ever been able to reach, and that small molecules cannot fully inhibit. Its Alphabodies are structurally distinct from antibodies and from most other scaffolds – they can be designed to penetrate cell membranes, to remain stable inside cells, and to bind intracellular targets.